NSE · SHILPAMED
Shilpa Medicare Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹189 Cr with net profit ₹65 Cr — a 34.34% net margin, versus 15.71% the period before.
Shareholding
As of 2026-06-30
- Promoter40.13%
- Public40.43%
- FII11.38%
- DII8.05%
60,926 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.78× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 1 · ST-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #6 of 50 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,88,872 Cr | 84.65 | 22.46 | 25.49% | 13.95% |
| Gland Pharma Limited | ₹48,208 Cr | 42.07 | 4.65 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹44,153 Cr | 38.91 | 9.75 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹30,382 Cr | 105.42 | 23.57 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd. | ₹20,940 Cr | 31.47 | 6.21 | 17.88% | 29.09% |
| Shilpa Medicare Ltd.(this company) | ₹18,798 Cr | 66.1 | 7.25 | 9.39% | 17.67% |
| Eris Lifesciences Limited | ₹18,785 Cr | 28.6 | 4.81 | 15.87% | 20.04% |
| Marksans Pharma Limited | ₹14,927 Cr | 28.89 | 4.94 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹7,666 Cr | 55.67 | 6.43 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,757 Cr | 53.47 | 7.24 | 12.36% | 18.59% |
AI analysis
AI-generated · google/gemini-2.5-flashShilpa Medicare Ltd. has a market capitalization of Rs 12233 Cr. The company reported revenue of Rs 1309.57 Cr with a profit margin of 15.81%. Its earnings per share (EPS) stands at Rs 11.93, with a return on equity (ROE) of 9.39% and return on capital employed (ROCE) of 10.73%. The debt-to-equity ratio is 0.36.
Positives
- +Revenue grew by 11.7% to Rs 1309.57 Cr.
- +The trailing twelve-month profit margin is 15.81%.
- +Debt-to-equity ratio is 0.36.
- +The company has a dividend yield of 10%.
Negatives
- −Promoter shareholding has decreased from 45.07% (Ramakant Innani) and 24.69% (Deepak Kumar Innani) to a total promoter holding of 40.1349% as of June 2026.
- −Promoters have pledged 8.73% of their shares, equivalent to specific individuals pledging shares such as Brijgopal Innani (400,000 shares) and Vishnukant Chaturbhuj Bhutada (2,000,000 shares).
Financial Performance
Shilpa Medicare Ltd. recorded revenue of Rs 1309.57 Cr in the last fiscal year, representing an 11.7% growth. The annual net profit for March 2025 was Rs 78.293 Cr. Quarterly revenues for Mar 2026 reached Rs 436.99 Cr, showing an increase from previous quarters such as Dec 2025 (Rs 410.28 Cr) and Sept 2025 (Rs 369.97 Cr). Net profit for Mar 2026 was Rs 107.79 Cr, a notable rise from Mar 2025 (Rs 14.51 Cr).
Profitability & Returns
The company’s profit margin is 15.81%. The return on equity (ROE) is 9.39% and the return on capital employed (ROCE) is 10.73%. Earnings per share (EPS) for the last reported period is Rs 11.93. The trailing twelve months EPS is Rs 11.93, while the reported EPS for March 2025 was Rs 8.04.
Balance Sheet
Shilpa Medicare Ltd. has a debt-to-equity ratio of 0.36, indicating a moderate level of debt relative to equity. The book value per share is Rs 132.49. The company maintains a dividend yield of 10% based on the current market price.
Ownership & Pledges
As of June 30, 2026, promoters held 40.1349% of the shares. Foreign Institutional Investors (FIIs) held 11.3827%, and Domestic Institutional Investors (DIIs) held 8.0528%. Public shareholding stood at 40.4296%. A total of 8.73% of promoter shares were pledged as of the latest reporting period. The number of shareholders as of June 2026 was 60,926.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.